Next-Generation Screening for Prostate Cancer
Working with colleagues at the University of Michigan, our team has helped to develop a new, highly accurate urine test for detection of higher-risk prostate cancer. The story of the novel test, called MyProstateScore 2.0 (MPS2), provides a great example of the teamwork needed to improve patient care – and how that teamwork begins and ends with patients themselves.
The MPS2 test measures a panel of 18 markers associated with prostate cancer and, for the first time, the high-grade aggressive prostate cancers that are most likely to cause harm. These novel markers were discovered in prostate cancer tissue samples from 775 patients across the country who participated in research efforts including The Cancer Genome Atlas project, among others. The MPS2 test was then developed in 761 patients that contributed urine samples prior to prostate biopsy at the University of Michigan. And the final step of “proving” the new test improves upon previously available tests? That was only possible because 743 patients across the country participated in a research study led by the National Cancer Institute. We are infinitely grateful for the selflessness of each patient today who chooses to contribute to research promising better cancer care tomorrow.
Click Here to read more about our collaborative, patient-focused efforts to improve the diagnosis and management of prostate cancer.